secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269654
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis posts record Q3 revenue of $150.5M, raises FY2025 guidance
------------------------------------------------------------------------

- Net product revenue $150.5M (+31% YoY); Advanced Wound Care $141.5M (+31%), Surgical & Sports Med $9.0M (+25%).
- Net income $21.6M ($0.11 diluted EPS) vs $12.3M ($0.09) YoY; adjusted net income $23.2M.
- Adjusted EBITDA $30.1M vs $13.4M YoY; operating income $20.7M vs $6.2M.
- FY2025 revenue guidance raised to $500-525M (4-9% YoY); Adj. net income guided $21.5-38.4M.
- Cash $64.4M, no debt; cash down from $136.2M due to operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000119312525269654/0001193125-25-269654-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000119312525269654/orgo-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269654

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer